Navigation Links
Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
Date:5/20/2011

ing the time until pain worsens.  XGEVA also offers the ease of every four weeks subcutaneous injection and no requirement for dose adjustment for changes in renal function. XGEVA has the potential to make a meaningful difference for patients with advanced cancer and their healthcare providers."

The CHMP positive opinion is based on three pivotal, Phase 3 head-to-head trials that evaluated the effectiveness of XGEVA versus Zometa® (zoledronic acid) at delaying SREs. The clinical program for XGEVA spanned more than 50 tumor types in over 5,700 patients. In the SRE trials, XGEVA demonstrated a clinically meaningful improvement in preventing SREs compared to Zometa.

Specifically, in patients with breast or prostate cancer and bone metastases, XGEVA was superior to Zometa in reducing the risk of SREs. In patients with bone metastases due to other solid tumors or multiple myeloma, XGEVA was non-inferior to Zometa in reducing the risk of SREs. In an integrated analysis of all three studies XGEVA was superior to Zometa in delaying time to first on-study SRE by 17 percent or 8.2 months (median time to first skeletal related event of 27.6 months for XGEVA and 19.4 months for Zometa, p <0.0001). In this analysis, XGEVA was also superior to Zometa in delaying time to first-and-subsequent on-study SRE by 18 percent (p<0.0001).

In patients with mild or no pain at baseline, time to worsening pain was delayed for XGEVA compared to Zometa (198 versus 143 days) (p=0.0002).  The time to pain improvement was similar for XGEVA and Zometa.

In these double-blind trials, XGEVA was administered every four weeks as a 120 mg subcutaneous injection, versus Zometa delivered every four weeks via a 15-minute intravenous infusion, with adjustments for kidney function per the requirements of the Zometa prescribing information. XGEVA was not associated with renal toxicity or acute phase reactions, both well known side effects of Zometa treatment. '/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 ... ) has announced the addition of the  ... 2014"  report to their offering.  ... and Chinese Acne Medication Industry Report 2014 ... the current state of the global acne ...
(Date:10/25/2014)... Oct. 24, 2014  As the building blocks ... company access to diverse skill sets and expertise, ... clock business hours for efficiency. However, effectively managing ... According to recent research, more than ... seeing a project not move forward due to ...
(Date:10/22/2014)... 22, 2014  Rescheduling of hydrocodone combination products ... pain market, according to a new primary market ... providing market research and consultation exclusively in the ... http://photos.prnewswire.com/prnh/20141021/153440 In August, ... combination products from Schedule III to Schedule II ...
Breaking Medicine Technology:Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... 2011 The GlaxoSmithKline 15th Annual IMPACT Awards target ... underserved. Up to ten organizations in the Pennsylvania Counties ... Philadelphia and in the City of Camden, New Jersey, ... are bestowed upon winning organizations for success and achievements ...
... American Scientific Resources, Inc. (Pink Sheets: ... non-contact thermometer. Updating the packaging to a brighter cleaner ... thermometer. "We made the changes to distance ... foreign model previously sold by American Scientific Resources; to ...
Cached Medicine Technology:GlaxoSmithKline 15th Annual IMPACT Awards Seek Philadelphia Area and Camden Healthcare Nonprofits 2American Scientific Resources Rebrands Non-Contact Thermometer for Mass Market Consumer Appeal 2
(Date:10/25/2014)... WI (PRWEB) October 25, 2014 ... tax-advantaged medical and other benefits account management services, ... to help employers save on taxes, reduce administrative ... Suites provide tax savings and the efficient handling ... pick the Suite that best meets their goals ...
(Date:10/25/2014)... New York (PRWEB) October 25, 2014 ... mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against ... underway in U.S. District Court, Southern District of ... Summary Judgment on Punitive Damages in a group ... In a ruling issued on October 21st, U.S. ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Not getting the ... ulcerative colitis, a new study suggests. Those who ... eight hours per night may be more prone to ... intestines, researchers report. The study authors concluded that duration ... considered among patients with inflammatory bowel diseases. "Both ...
(Date:10/25/2014)... News) -- October,s shorter, darker days can trigger a ... to an expert. People affected by seasonal ... lack motivation and even have trouble getting out of ... said Dr. Angelos Halaris, a professor in the department ... Stitch School of Medicine. "Seasonal affective disorder should ...
(Date:10/22/2014)... MI (PRWEB) October 22, 2014 ... Schools of Allied Health Professions (ASAHP) Conference on October ... and CEO will participate in a panel discussion on ... Practice. , Isabel Healthcare provides a diagnostic decision support ... improving the diagnosis skills of students and clinical learners. ...
Breaking Medicine News(10 mins):Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... manufactured by Merck & Co would result in an increased ... taking the drug. // Statistics show that about 60 patients ... six to 13 days after they first started taking Vioxx. ... Journal. It was contrary to what Merck had previously told ...
... of the Food and Drug Administration has been subjected ... // ,Attorney Barbara Van Gelder has mentioned ... of Lester Crawford. She is believed to have ... Thursday, that she would instruct him to invoke his ...
... and polio immunization campaign commenced with a bit of ... with their children to avail immunization, // and this ... Infact, the stock of vaccines started getting depleted by ... of the vaccination drive. ,Assistant Minister for Medical ...
... hypothermia to help patients with severe heart disease or ... Dalton Dietrich and his colleagues noticed// that the rats ... stroke, but had different responses. ,"We ... temperatures in the rats' brains they found that rates ...
... University Medical School in Melbourne, Australia, it was found ... than a very low-calorie diet.// The surgical procedure consists ... stomach to create a feeling of fullness in patients ... those who have serious medical conditions, such as type ...
... A study conducted by a Brown Medical School professor ... say that postpartum depression is linked to fussy babies.//, ... clinical professor of paediatrics at Brown Medical School and ... Other members include Rhode Island Department of Health's Division ...
Cached Medicine News:
... Used to establish and maintain ... ureteral segment promotes patency and allows ... subsides. Supplied sterile in peel-open packages. ... evaluation is advised; stent must not ...
... drainage following open renal or bladder ... provide enhanced drainage and promote catheter ... for enhanced patient comfort and provides ... Supplied sterile in peel-open packages. Intended ...
... Used for percutaneous ... catheter in the renal ... Supplied sterile in peel-open ... use. CAUTION: Periodic evaluation ...
... contains primers and a FAM-labeled probe targeting the ... Parvo B19 ASR contains primers and a Texas ... ASR requires an instrument that can detect FAM ... The Cepheid Analyte Specific Reagent* (ASR) program is ...
Medicine Products: